Xilio Therapeutics (XLO) Free Cash Flow Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Xilio Therapeutics |
144.35 Mn |
-5.95 Mn |
- |
-179.83% |
| Date | Value |
|---|
| Mar 31, 2026 |
-179.83% |
| Dec 31, 2025 |
85.22% |
| Sep 30, 2025 |
-27.88% |
| Jun 30, 2025 |
-173.21% |
| Mar 31, 2025 |
372.60% |
| Dec 31, 2024 |
-5.48% |
| Sep 30, 2024 |
-2.33% |
| Jun 30, 2024 |
218.13% |
| Mar 31, 2024 |
58.60% |
| Dec 31, 2023 |
24.87% |
| Sep 30, 2023 |
30.57% |
| Jun 30, 2023 |
3.63% |
| Mar 31, 2023 |
-20.54% |
| Dec 31, 2022 |
-5.25% |
| Sep 30, 2022 |
7.57% |
| Jun 30, 2022 |
14.48% |
| Mar 31, 2022 |
8.24% |
| Dec 31, 2021 |
-32.51% |
